Background: Continuous anticoagulation guided by the CHA2DS2-VASc score is standard for atrial fibrillation (AF) but does not reflect real-time AF occurrence. We evaluated an Apple Watch-guided event-triggered anticoagulation strategy that adjusts direct oral anticoagulant (DOAC) use according to smartwatch detection.
The Apple Watch helps people with a heart condition called atrial fibrillation manage their blood-thinning medication. By using this smartwatch, doctors can see when AF happens and change medications right away. This way, treatment is smarter and can help prevent serious issues. It’s a cool way to use technology to improve heart health! ⌚️
To assess the effectiveness of an Apple Watch-guided anticoagulation strategy for patients after atrial fibrillation ablation.
Other
Atrial fibrillation post-ablation (n=54)
Apple Watch-guided event-triggered anticoagulation vs. Continuous anticoagulation
Apple Watch-guided event-triggered anticoagulation reduced DOAC exposure by 94.6% compared with continuous anticoagulation in post-ablation atrial fibrillation patients, with no thromboembolic events.